喘或慢性阻塞性肺病和帕金森病风险中的β2-腺素受体激活剂:嵌套病例对照研究
Anne Paakinaho1, Miia Tiihonen1, Heikki Koskela2,3
1School of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, Kuopio, Finland.
Clinical epidemiology
|June 19, 2023
概括
吸入的β2-上腺受体 (β2AR) 激动剂与降低帕金森病 (PD) 风险没有一致的联系. 然而,长效β2AR激动剂的最高平均年暴露在喘患者中显示了潜在的PD风险降低.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 流行病学 流行病学
背景情况:
- 贝塔2-上腺受体 (β2AR) 激动剂用于喘和COPD.
- 以前的研究表明β2AR激动剂与降低帕金森病 (PD) 风险之间存在潜在联系,但研究结果尚不确定.
- 根据指示进行混可能会影响观察到的关联.
研究的目的:
- 调查吸入β2AR激动剂与患有喘或慢性阻塞性肺病 (COPD) 个体的PD风险之间的关联.
主要方法:
- 一项嵌套病例控制研究 (FINPARK) 包括1406例PD病例和8630个与喘/COPD匹配的对照.
- 对短效和长效β2AR激动剂的暴露在3年滞后期间使用定义的每日剂量 (DDDs) 进行评估.
- 条件后勤回归被用来计算调整的赔率比率 (aORs).
主要成果:
- 对β2AR激动剂的累积暴露与PD风险没有关联.
- 只有对长效β2AR激动剂平均年暴露的最高四分位数 (aOR 0.75;95% CI 0.58-0.97) 观察到PD风险降低.
- 分层分析表明,喘和COPD患者的风险估计最低.
结论:
- 对β2AR激动剂的更高暴露水平并不始终与PD风险降低有关.
- 观察到与长效β2AR激动剂的逆相关性可能受到未测量的混因素的影响,如疾病严重程度或吸烟.
相关概念视频
Antiasthma Drugs: β2-Adrenoceptor Agonists
317
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
317
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
895
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
895
Adrenergic Antagonists: ɑ and β-Receptor Blockers
524
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
524
Antihypertensive Drugs: Types of β-Blockers
764
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
764
Parkinson's Disease: Treatment
303
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
303
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
892
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
892


